CXCR6 and metabolic dysfunction-associated steatotic liver disease: Therefore, the CXCL16/CXCR6 axis may be a potential therapeutic target for tumors [38,40,41,42], kidney diseases [36,42], cardiovascular diseases [36,42], non-alcoholic fatty liver disease 43, and autoimmune diseases [37].